Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2019, No. 2


Bozada-Gutiérrez KE, Fresán-Orellana A, Yamamoto-Furusho JK
Validación de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal
Gac Med Mex 2019; 155 (2)

Idioma: Español
Referencias bibliográficas: 29
Paginas: 124-129
Archivo PDF: 234.52 Kb.


Texto completo




RESUMEN

Introducción: La adherencia terapéutica es crucial en la enfermedad inflamatoria intestinal (EII) para evitar recaídas y complicaciones. En México no se dispone de una herramienta validada para evaluar adherencia en pacientes con EII. Objetivo: Traducir los instrumentos Belief Medicines Questionnaire (BMQ) y Self-Efficacy for Appropriate Medication Use Scale (SEAMS), y determinar su validez, fiabilidad y sensibilidad en pacientes mexicanos con diagnóstico de EII. Método: Se incluyeron 149 pacientes con diagnóstico de EII, previo consentimiento informado. Se tradujeron los instrumentos al español y posteriormente fueron aplicados durante la consulta médica. Para la SEAMS se realizó análisis factorial exploratorio, análisis de curva ROC y determinación del alpha de Cronbach; para el BMQ se empleó el coeficiente kappa de Cohen y su capacidad predictiva. Resultados: Se incluyeron 75 mujeres (50.3 %) con edad promedio de 44 años. La escala SEAMS mostró un único factor altamente confiable (alfa de Cronbach = 0.92) y un punto de corte de 33 para identificar a los pacientes adherentes. Las dimensiones “adherencia” y “barrera de recuerdo” del BMQ fueron adecuados predictores de adherencia. Conclusiones: Las versiones en español SEAMS y BMQ son válidas para medir autoeficacia y barreras para la adherencia al tratamiento farmacológico en pacientes mexicanos con EII.


Palabras clave: Adherencia, Autoeficacia, Barreras, Tratamiento farmacológico, Enfermedad inflamatoria intestinal.


REFERENCIAS

  1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361 2066-2078.

  2. Sabaté E. Adherence to long-term therapies: evidence for action. Suiza: World Health Organization; 2003.

  3. Mårdby AC, Åkerlind I, Jörgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns. 2007; 69:158-164.

  4. Kane S V, Robinson A. Understanding adherence to medication in ulcerative colitis–innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010;32:1051-1058.

  5. Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12:132.

  6. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26:936-946.

  7. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247-257.

  8. Van Staa TP, Card T, Logan RF, Leufkens HG. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.

  9. Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel‐Wood M. Longterm oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-764.

  10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.

  11. Nguyen TMU, La-Caze A, Cottrell N. What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427-445.

  12. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986: 24:67-74.

  13. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Heal. 2002;17:17-32.

  14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Heal. 1999;14:1-24.

  15. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. 2007;15 203-219.

  16. Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982;37:122.

  17. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med. 1997;19:239-263.

  18. Perpiñá-Tordera M, Martínez-Moragón EM, Belloch-Fuster A, Lloris- Bayo A, Pellicer-Císcar C. Spanish asthma patients’ beliefs about health and medicines: validation of 2 questionnaires. Arch Bronconeumol. 2009; 45:218-223.

  19. Fall E, Gauchet A, Izaute M, Horne R, Chakroun N. Validation of the French version of the Beliefs about Medicines Questionnaire (BMQ) among diabetes and HIV patients. Rev Eur Psychol Appliquée/European Rev Appl Psychol. 2014;64 335-343.

  20. Jónsdóttir H, Friis S, Horne R, Pettersen KI, Reikvam Å, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009; 119:78-84.

  21. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford). 2005; 44:762-767.

  22. Horne R, Parham R, Driscoll R, Robinson A. Patient’s attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837-844.

  23. Pan Y, De la Puente M. Census bureau guideline for the translation of data collection instruments and supporting materials: documentation on how the guideline was developed. Surv Methodol. 2005;6.

  24. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2014;54:494-499.

  25. Giordano TP, Guzmán D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.

  26. Pedrosa RB, Rodrigues RC, Oliveira HC, Alexandre NM. Construct validity of the Brazilian version of the Self-Efficacy for Appropriate Medication Adherence Scale. J Nurs Meas. 2016;24:18-31.

  27. Dong XF, Liu YJ, Wang AX, Lv PH. Psychometric properties of the Chinese version of the Self-Efficacy for Appropriate Medication Use Scale in patients with stroke. Patient Prefer Adherence. 2016;10:321-327.

  28. Michetti P, Weinman J, Mrowietz U, Smolen J, Louis E, Peyrin-Biroulet L, et al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv Ther. 2017;34:91-108.

  29. De Castro ML, Sanromán L, Martín A, Martínez N, Hernández V, Del Campo V, et al. Valoración de la adhesión terapéutica en la enfermedad inflamatoria intestinal. Comparación entre una escala de autoevaluación y un índice farmacéutico de dispensación de medicamentos. Rev Esp Enferm Dig. 2017;109 542-551.



>Revistas >Gaceta Médica de México >Año2019, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019